Quantitative magnetic resonance imaging (MRI) has emerged as a powerful tool for assessing disease progression by providing objective, reproducible, and biologically meaningful biomarkers. Unlike conventional qualitative MRI, quantitative techniques generate measurable parameters that reflect underlying tissue microstructure, physiology, and metabolism, enabling earlier and more sensitive detection of pathological changes. This narrative review summarizes current evidence on the role of quantitative MRI biomarkers in monitoring disease progression across neurological, oncological, musculoskeletal, and cardiovascular conditions. Key techniques discussed include T1 and T2 mapping, diffusion MRI metrics such as apparent diffusion coefficient and fractional anisotropy, perfusion MRI parameters, and magnetic resonance spectroscopy–based metabolic markers. The review highlights how these biomarkers correlate with clinical outcomes, track longitudinal changes, and often identify disease progression earlier than standard imaging. Clinical applications, strengths, and limitations of each technique are discussed in simple and practical terms, with emphasis on their translational value in routine practice and research. Challenges related to standardization, inter-scanner variability, and integration into clinical workflows are also addressed. Overall, quantitative MRI biomarkers represent an important advancement in imaging, offering improved disease monitoring, better treatment response assessment, and enhanced support for personalized patient care.

Keywords: Quantitative MRI, Imaging Biomarkers, Disease Progression, Diffusion MRI